Information  X 
Enter a valid email address

Kropz PLC (KRPZ)


Monday 11 October, 2021

Kropz PLC

Update on New Convertible Facility Agreement

RNS Number : 5546O
Kropz PLC
11 October 2021

11 October 2021

Kropz Plc

("Kropz" or the "Company")

Update on New Convertible Facility Agreement

Kropz Plc (AIM: KRPZ), an emerging African phosphate explorer and developer, announced on 29 September 2021 that it had entered into a new conditional convertible equity facility of up to ZAR 200 million ("New ZAR Equity Facility"), with ARC Fund ("ARC"), the Company's major shareholder, in order to deliver the Company's Elandsfontein phosphate project to first revenue. 

Further to that announcement, the Company is pleased to report that it has now received approval from the South African Reserve Bank ("SARB") for the New ZAR Equity Facility. The New ZAR Equity Facility is also conditional on shareholder approval which, as previously announced, is being sought from the Company's shareholders at a General Meeting to be held in London at 11:30 on 15 October 2021.

For further information visit  or contact:


Kropz Plc

Mark Summers (CEO)

+27 (0) 79 744 8708

Grant Thornton UK LLP

Nominated Adviser

Samantha Harrison

Harrison Clarke

George Grainger

+44 (0) 20 7383 5100


Hannam & Partners


Andrew Chubb

Ernest Bell

+44 (0) 20 7907 8500


Financial PR & IR (UK)

Nick Elwes

Jos Simson

Oliver Lamb

+44 (0) 207 920 3150

[email protected]

R&A Strategic Communications

PR (South Africa)

James Duncan

+27 (0) 11 880 3924

[email protected]


About Kropz Plc

Kropz is an emerging African explorer and developer of plant nutrient feed minerals with phosphate projects in South Africa and in the Republic of Congo. The vision of the Group is to become a leading independent phosphate rock producer and to develop into an integrated, mine-to-market plant nutrient company focusing on sub-Saharan Africa.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns[email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t